Tur, Carmen
Moccia, Marcello
Barkhof, Frederik
Chataway, Jeremy
Sastre-Garriga, Jaume
Thompson, Alan J.
Ciccarelli, Olga
Article History
First Online: 12 January 2018
Competing interests
: C.T. declares that she has received honoraria and support for travelling from Bayer Schering, Biogen, Ismar Healthcare, Merck Serono, Novartis, Sanofi–Aventis, Serono Foundation and Teva. M.M. declares that he has received honoraria and support for travelling from Almirall, Coloplast, Genzyme and Merck Serono. F.B. declares that he has received consulting fees for participating in steering committees, data-safety monitoring boards and advisory boards from Bayer Schering, Biogen, Genzyme, Jansen Research, Merck Serono, Novartis, Roche, Sanofi–Aventis, Synthon and Teva. J.C. declares that he has been a principal investigator for trials in multiple sclerosis funded by Biogen, Novartis and Receptos and additionally received an investigator grant from Novartis; he has also participated in advisory boards and/or received consultancy fees from Apitope, Biogen, MedDay, Merck and Roche. J.S.-G. declares that he has received speaker's honoraria from and/or participated in advisory boards for Almirall, Biogen, Celgene, Genzyme, Merck, Novartis and Teva. A.J.T. declares that he has received honoraria and/or support for travel for consultancy from Biogen (Optum Insight), Eisai and Excemed and support for travel from the International Progressive Multiple Sclerosis Alliance (as chair of their Scientific Steering Committee) and from the US National Multiple Sclerosis Society (as a member of their Research Programs Advisory Committee); he also receives an honorarium from SAGE Publishers as Editor in Chief of <i>Multiple Sclerosis Journal</i>. O.C. declares that she has received fees for consultancy from Biogen, Genzyme, Novartis, Roche and Teva and an honorarium for her position as an associate editor of <i>Neurology</i>.